Development of a LC-MS/MS-based method for determining metolazone concentrations in human plasma

Application to a pharmacokinetic study

Yen An Chen, Kuang Yang Hsu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In this study, a method was developed and validated for the quantification of metolazone in human plasma samples. This method involves high-performance liquid chromatography coupled with tandem mass spectrometry and is more sensitive, selective and rapid than currently available methods. Chromatography was performed using a Phenomenex® Luna C18 column (100 mm x 2.0 mm, 5 μm, 100 Å) with an isocratic mobile phase of 0.1% formic acid:acetonitrile (40:60, v/v) and zaleplon as an internal standard. The drug and internal standard were extracted by liquid-liquid extraction and analyzed by mass spectrometry in the multiple reaction monitoring mode by using m/z values of 366.20/259.10 for metolazone and 306.20/235.60 for zaleplon. The calibration curve was linear over metolazone concentrations ranging from 0.02 ng/mL to 15 ng/mL. The lower limit of quantification was 0.02 ng/mL. Intra- and inter-assay precisions were 0.9-4.8% and 4.2-6.3%, respectively. The intra- and inter-assay accuracies in quantifying metolazone were 97.5-102.3% and 99.2-104.0%, respectively. Metolazone and zaleplon were eluted within 3.6 minutes, and the retention time was 1.75 minutes for metolazone and zaleplon. The validated method was successfully applied to a pharmacokinetic study of metolazone in human plasma.

Original languageEnglish
Pages (from-to)154-159
Number of pages6
JournalJournal of Food and Drug Analysis
Volume21
Issue number2
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Metolazone
zaleplon
pharmacokinetics
Pharmacokinetics
assays
formic acid
methodology
chromatography
calibration
high performance liquid chromatography
mass spectrometry
Liquid-Liquid Extraction
drugs
Tandem Mass Spectrometry
tandem mass spectrometry
monitoring
Calibration
Chromatography
Mass Spectrometry
High Pressure Liquid Chromatography

Keywords

  • Liquid chromatography
  • Mass spectrometry
  • Metolazone
  • Pharmacokinetic study

ASJC Scopus subject areas

  • Food Science
  • Pharmacology

Cite this

Development of a LC-MS/MS-based method for determining metolazone concentrations in human plasma : Application to a pharmacokinetic study. / Chen, Yen An; Hsu, Kuang Yang.

In: Journal of Food and Drug Analysis, Vol. 21, No. 2, 06.2013, p. 154-159.

Research output: Contribution to journalArticle

@article{1546436bb17f4ab3ab920cb02eb335be,
title = "Development of a LC-MS/MS-based method for determining metolazone concentrations in human plasma: Application to a pharmacokinetic study",
abstract = "In this study, a method was developed and validated for the quantification of metolazone in human plasma samples. This method involves high-performance liquid chromatography coupled with tandem mass spectrometry and is more sensitive, selective and rapid than currently available methods. Chromatography was performed using a Phenomenex{\circledR} Luna C18 column (100 mm x 2.0 mm, 5 μm, 100 {\AA}) with an isocratic mobile phase of 0.1{\%} formic acid:acetonitrile (40:60, v/v) and zaleplon as an internal standard. The drug and internal standard were extracted by liquid-liquid extraction and analyzed by mass spectrometry in the multiple reaction monitoring mode by using m/z values of 366.20/259.10 for metolazone and 306.20/235.60 for zaleplon. The calibration curve was linear over metolazone concentrations ranging from 0.02 ng/mL to 15 ng/mL. The lower limit of quantification was 0.02 ng/mL. Intra- and inter-assay precisions were 0.9-4.8{\%} and 4.2-6.3{\%}, respectively. The intra- and inter-assay accuracies in quantifying metolazone were 97.5-102.3{\%} and 99.2-104.0{\%}, respectively. Metolazone and zaleplon were eluted within 3.6 minutes, and the retention time was 1.75 minutes for metolazone and zaleplon. The validated method was successfully applied to a pharmacokinetic study of metolazone in human plasma.",
keywords = "Liquid chromatography, Mass spectrometry, Metolazone, Pharmacokinetic study",
author = "Chen, {Yen An} and Hsu, {Kuang Yang}",
year = "2013",
month = "6",
doi = "10.1016/j.jfda.2013.05.004",
language = "English",
volume = "21",
pages = "154--159",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "Elsevier Taiwan LLC",
number = "2",

}

TY - JOUR

T1 - Development of a LC-MS/MS-based method for determining metolazone concentrations in human plasma

T2 - Application to a pharmacokinetic study

AU - Chen, Yen An

AU - Hsu, Kuang Yang

PY - 2013/6

Y1 - 2013/6

N2 - In this study, a method was developed and validated for the quantification of metolazone in human plasma samples. This method involves high-performance liquid chromatography coupled with tandem mass spectrometry and is more sensitive, selective and rapid than currently available methods. Chromatography was performed using a Phenomenex® Luna C18 column (100 mm x 2.0 mm, 5 μm, 100 Å) with an isocratic mobile phase of 0.1% formic acid:acetonitrile (40:60, v/v) and zaleplon as an internal standard. The drug and internal standard were extracted by liquid-liquid extraction and analyzed by mass spectrometry in the multiple reaction monitoring mode by using m/z values of 366.20/259.10 for metolazone and 306.20/235.60 for zaleplon. The calibration curve was linear over metolazone concentrations ranging from 0.02 ng/mL to 15 ng/mL. The lower limit of quantification was 0.02 ng/mL. Intra- and inter-assay precisions were 0.9-4.8% and 4.2-6.3%, respectively. The intra- and inter-assay accuracies in quantifying metolazone were 97.5-102.3% and 99.2-104.0%, respectively. Metolazone and zaleplon were eluted within 3.6 minutes, and the retention time was 1.75 minutes for metolazone and zaleplon. The validated method was successfully applied to a pharmacokinetic study of metolazone in human plasma.

AB - In this study, a method was developed and validated for the quantification of metolazone in human plasma samples. This method involves high-performance liquid chromatography coupled with tandem mass spectrometry and is more sensitive, selective and rapid than currently available methods. Chromatography was performed using a Phenomenex® Luna C18 column (100 mm x 2.0 mm, 5 μm, 100 Å) with an isocratic mobile phase of 0.1% formic acid:acetonitrile (40:60, v/v) and zaleplon as an internal standard. The drug and internal standard were extracted by liquid-liquid extraction and analyzed by mass spectrometry in the multiple reaction monitoring mode by using m/z values of 366.20/259.10 for metolazone and 306.20/235.60 for zaleplon. The calibration curve was linear over metolazone concentrations ranging from 0.02 ng/mL to 15 ng/mL. The lower limit of quantification was 0.02 ng/mL. Intra- and inter-assay precisions were 0.9-4.8% and 4.2-6.3%, respectively. The intra- and inter-assay accuracies in quantifying metolazone were 97.5-102.3% and 99.2-104.0%, respectively. Metolazone and zaleplon were eluted within 3.6 minutes, and the retention time was 1.75 minutes for metolazone and zaleplon. The validated method was successfully applied to a pharmacokinetic study of metolazone in human plasma.

KW - Liquid chromatography

KW - Mass spectrometry

KW - Metolazone

KW - Pharmacokinetic study

UR - http://www.scopus.com/inward/record.url?scp=84881459227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881459227&partnerID=8YFLogxK

U2 - 10.1016/j.jfda.2013.05.004

DO - 10.1016/j.jfda.2013.05.004

M3 - Article

VL - 21

SP - 154

EP - 159

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 2

ER -